Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 11/20 | 0.44 |
| ▸ | MTOR | P42345 | 10/20 | 0.44 |
| ▸ | ATR | Q13535 | 6/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7878799 | 1.00 | ATM (0.44) | ATMMTORATRPIK3CAPIK3CD | |
| SCHEMBL3515818 | 0.90 | ATM (0.44) | ATMMTORATRPIK3CAPIK3CD | |
| SCHEMBL3515975 | 0.90 | ATM (0.44) | ATMMTORATRPIK3CAPIK3CD | |
| SCHEMBL3516026 | 0.90 | ATM (0.44) | ATMMTORATRPIK3CAPIK3CD | |
| SCHEMBL7878044 | 0.86 | MTOR (0.43) | ATMMTORATRPIK3CAPIK3CD | |
| SCHEMBL7874775 | 0.86 | MTOR (0.43) | ATMMTORATRPIK3CAPIK3CD | |
| SCHEMBL2067655 | 0.85 | ATM (0.49) | ATMMTORATRPIK3CAPIK3CD | |
| SCHEMBL2068075 | 0.85 | ATM (0.49) | ATMMTORATRPIK3CAPIK3CD | |
| SCHEMBL2068161 | 0.85 | ATM (0.49) | ATMMTORATRPIK3CAPIK3CD | |
| SCHEMBL2068931 | 0.83 | ATM (0.48) | ATMMTORATRPIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |